The American Journal of Psychiatry
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
* Citation Map
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via HighWire
* Citing Articles via Google Scholar
Google Scholar
* Articles by Schildkraut, J. J.
* Articles by Mooney, J. J.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Schildkraut, J. J.
* Articles by Mooney, J. J.
Related Collections
* Neurotransmitters
* Antidepressants
Am J Psychiatry 161:909-911, May 2004
© 2004 American Psychiatric Association


Brief Report

Toward a Rapidly Acting Antidepressant: The Normetanephrine and Extraneuronal Monoamine Transporter (Uptake 2) Hypothesis

Joseph J. Schildkraut, M.D., and John J. Mooney, M.D.

OBJECTIVE: The authors considered the possible role of the extraneuronal monoamine transporter (uptake 2) in accounting for the delay in clinical action of norepinephrine reuptake inhibitor antidepressant drugs. METHOD: Literature searches were performed by means of the MEDLINE and Current Contents databases with search terms such as "extraneuronal uptake," "uptake 2," "extraneuronal monoamine transporter," and "organic cation transporter type-3." RESULTS: The findings in this literature indicate that inhibition of glial uptake 2 by normetanephrine or other inhibitors of uptake 2 would enhance the accumulation of norepinephrine in the synapse. CONCLUSIONS: The authors propose the hypothesis that drugs or other agents that increase levels of normetanephrine or otherwise inhibit the extraneuronal monoamine transporter, uptake 2, in the brain will speed up the clinical effects of norepinephrine reuptake inhibitor antidepressant drugs.




This article has been cited by other articles:


Home page
Proc. Natl. Acad. Sci. USAHome page
N. L. Baganz, R. E. Horton, A. S. Calderon, W. A. Owens, J. L. Munn, L. T. Watts, N. Koldzic-Zivanovic, N. A. Jeske, W. Koek, G. M. Toney, et al.
Organic cation transporter 3: Keeping the brake on extracellular serotonin in serotonin-transporter-deficient mice
PNAS, December 2, 2008; 105(48): 18976 - 18981.
[Abstract] [Full Text] [PDF]


Home page
Psychosom. Med.Home page
B. H. Brummett, A. D. Krystal, I. C. Siegler, C. Kuhn, R. S. Surwit, S. Zuchner, A. Ashley-Koch, J. C. Barefoot, and R. B. Williams
Associations of a Regulatory Polymorphism of Monoamine Oxidase-A Gene Promoter (MAOA-uVNTR) With Symptoms of Depression and Sleep Quality
Psychosom Med, June 1, 2007; 69(5): 396 - 401.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
Y. Alnouti, J. S. Petrick, and C. D. Klaassen
TISSUE DISTRIBUTION AND ONTOGENY OF ORGANIC CATION TRANSPORTERS IN MICE
Drug Metab. Dispos., March 1, 2006; 34(3): 477 - 482.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
G. Horvath and A. Wanner
Inhaled corticosteroids: effects on the airway vasculature in bronchial asthma
Eur. Respir. J., January 1, 2006; 27(1): 172 - 187.
[Abstract] [Full Text] [PDF]




Get information about faster international access.

Privacy Policy

Copyright © 2004 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Psychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org